BBIO

Bridgebio Pharma, Inc.

A biopharmaceutical company developing medicines for genetic diseases, BridgeBio's approved products include Attruby for a heart condition called ATTR-CM and Truseltiq for bile-duct cancer. Founded in 2015, its name reflects a mission of 'bridging' genetic research to patients, and it runs a hub-and-spoke model where small teams advance each drug. Its experimental oral therapy for achondroplasia was the first-ever treatment for children with the condition to earn the FDA's Breakthrough Therapy designation.

Recent Activity

Show $

2026Q2

1 buy2 sells

Bridgewater Associates LPADD

+188.7K shares(+72.7%)

Bridgewater Associates LPADD

+188.7K shares(+72.7%)

Polen Capital ManagementTRIM

-41.9K shares(-91.3%)

Polen Capital ManagementTRIM

-41.9K shares(-91.3%)

Viking Global InvestorsTRIM

-1.89M shares(-16.0%)

Viking Global InvestorsTRIM

-1.89M shares(-16.0%)

2026Q1

2 buys2 sells

ArrowMark PartnersEXIT

-110.0K shares

ArrowMark PartnersEXIT

-110.0K shares

Bridgewater Associates LPADD

+216.3K shares(+501.0%)

Bridgewater Associates LPADD

+216.3K shares(+501.0%)

Polen Capital ManagementADD

+7.7K shares(+20.1%)

Polen Capital ManagementADD

+7.7K shares(+20.1%)

Viking Global InvestorsTRIM

-2.55M shares(-17.7%)

Viking Global InvestorsTRIM

-2.55M shares(-17.7%)

Loading more activity...